Genetron Health

Genetron Health (NASDAQ: GTH) is a global leading cancer precision medicine company, focusing on cancer genomics research and applications, and committed to transforming cancer diagnosis and treatment through advanced molecular biology and big data analysis capabilities. Genetron Health has developed a comprehensive product and service pipeline covering the entire cancer care cycle, from early screening to diagnosis and treatment recommendations, to monitoring and prognosis management, and actively explores more innovative application directions and scenarios of molecular testing technology with upstream and downstream partners in the industry chain.

Genetron Health has served over 500 hospitals in China, dozens of pharmaceutical companies and research institutions, and has established a vast genomic database. In the field of diagnosis and monitoring, Genetron Health provides comprehensive molecular testing services and products, covering eight of the top ten cancer types in China, and can perform tissue testing and liquid biopsy (blood, urine, cerebrospinal fluid, etc.). Relying on proprietary technologies such as the "One-Step Method" (Chinese invention patent ZL 201710218529.4), it has developed a comprehensive VD product portfolio on three technology platforms: NGS, dPCR, and qPCR. Currently, 7 instruments and reagent kits have been approved for clinical use by China's National Medical Products Administration, and another 7 products are in the development and clinical trial validation stage. In the field of early cancer screening, Genetron Health has taken the lead in making significant breakthroughs in liver cancer. Its self-developed liquid biopsy product for early hepatocellular carcinoma screening, HCCscreenTM, has been granted "Breakthrough Device Designation" by the U.S. FDA. Additionally, leveraging its proprietary Mutation CapsuleTM technology (which can simultaneously detect cfDNA mutations and methylation), it has joined multiple national key research projects led by the Ministry of Science and Technology involving liver cancer, lung cancer, and gastrointestinal cancer, and has launched prospective cohort studies on a scale of hundreds of thousands. In the field of drug development services, Genetron Health has established strategic partnerships with dozens of domestic and international pharmaceutical companies to meet their needs in early drug development, drug target screening, clinical trial testing, patient enrollment, companion diagnostic (CDx) registration and development, and commercialization.

Genetron Health operates dual research and development centers in China and the United States, two medical device production bases certified under ISO13485:2016 and ISO9001:2015, and five medical testing laboratories located in Beijing (with both CAP and CLIA certifications), Shanghai, Hangzhou, Chongqing, and Guangzhou. The company's scientist team, with world-class R&D capabilities, remains at the forefront of cancer genomics research, having published dozens of papers in leading international journals such as Nature Genetics, Nature Communications, Cell Research, and PNAS, and has filed dozens of domestic and international patents.